A protein that can dial down oxidative stress in cells helps some cancers resist treatment with a widely used class of drugs ...
Clinical data from the HERCULES trial show that tolebrutinib reduces six-month confirmed disability progression by 31% in non ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results